Antibiotic resistance is one of the biggest threats to public health. The rapid emergence of resistant bacterial pathogens endangers the efficacy of current antibiotics and has led to increasing mortality and economic burden. This crisis calls for more rapid and accurate diagnosis to detect and identify pathogens, as well as to characterize their response to antibiotics. Building on this foundation, treatment options also need to be improved to use current antibiotics more effectively and develop alternative strategies that complement the use of antibiotics. We here review recent developments in diagnosis and treatment of bacterial pathogens with a focus on quantitative biology and synthetic biology approaches.
Introduction
The discovery of penicillin by Alexander Fleming brought forth the golden age of antibiotics. Safe and highly effective prevention and treatment of bacterial infections enabled modern surgeries and immunosuppressive therapies. Due to the success of antibiotics, it was once thought that bacterial infections would be fully curable [1] . Decades later, clinically significant resistance against all current antibiotics has been observed [2, 3] . Furthermore, due to the low financial incentives for developing new antibiotics in the pharmaceutical industry, the antibiotic pipeline is drying up, leaving few options to treat infections caused by resistant pathogens [1] . As a result, the mortality and economic burden caused by resistant bacteria have been increasing globally [4] .
Antibiotic resistance is an inevitable and complex issue. Being a natural feature of microbial systems [5] , antibiotic resistance has been present on earth for millions of years without human influence [6] . In the past several decades, however, humans have generated considerable selection pressure for resistance, partly through antibiotic misuse and overuse [7] . Notably, human use is only a fraction of the total, with livestock receiving the majority of antibioticsdoften for non-therapeutic purposes [8] . Following consumption, an estimated 75%e90% of antibiotics are excreted unmetabolized into water systems and the environment at large [9, 10] , that generate prolonged sub-lethal selection gradients that can enrich resistant bacteria [11] . The complex dynamics of bacterial response to antibiotics is a fundamental, but often overlooked aspect of this issue [12, 13] . For example, bacterial cells that enter dormant states (persistence), where the cells do not divide or divide slowly, can tolerate higher doses of antibiotic than growing cells [14, 15] . Bacterial populations can also collectively survive antibiotic treatments that are lethal to individual cells, leading to collective antibiotic tolerance [13, 16] . From an evolutionary perspective, bacteria can gain antibiotic resistance through de novo mutations or horizontal gene transfer, which are processes that are confounded by environmental and genetic context [17] .
Advances in both diagnostics and treatments are critical for addressing the antibiotic resistance crisis (Fig. 1) . Rapid and accurate diagnosis is a necessary first step to develop effective, targeted treatment to reduce overuse and misuse of antibiotics. Timely administration of appropriate antibiotics is associated with significant improvement of treatment outcome [18] . In contrast, improper diagnosis can lead to ineffective treatments that promote evolution of antimicrobial resistance [19] or increase the susceptibility of patients to secondary infections [20] . As for treatment, antibiotics will likely remain the most dominant approach to combat bacterial infections in the near future despite increasing resistance. A better understanding of bacterial response to antibiotics is key to optimizing antibiotic treatment design. In the long term, if dependency on antibiotics continues, resistance may continue to rise. To overcome this, alternative treatments are needed to diversify treatment options, which can potentially alleviate our dependence on antibiotics. Here we review recent developments in quantitative biology and synthetic biology that improve diagnosis and treatment of bacterial pathogens in light of the antibiotic resistance crisis.
Diagnosis: identification, detection, and drug response
In general, diagnosis aims to detect and identify specific pathogens and characterize how they respond to different drugs. Detection and identification can be carried out with biochemical assays such as immunoassays [21] or sequence-dependent techniques such as whole-genome sequencing [22, 23] , ribosomal RNA sequencing [24, 25] and polymerase chain reactions [26, 27] . Characterization of drug responses is often accomplished by measuring growth of bacterial isolates in liquid culture or on solid agar in the presence of various antibiotics at different concentrations [28, 29] . Recent studies have demonstrated the promise of new engineered genetic devices and quantitative techniques in complementing existing technologies for both goals.
Detection and identification
Synthetic biology uses rationally designed biological parts to sense and report biomarkers for the detection and identification of bacterial pathogens and their resistance. Synthetic biology approaches aim to be modular: with proper design and implementation, individual modules, such as sensing, processing, and effector modules can be replaced depending on design goals without drastically affecting functions of other modules [30, 31] . This quality could speed up designeimplementation cycles [32, 33] Fig. 2A) . These cell-free sensors were rapidly prototyped to detect specific viral genes and antibiotic resistance genes, suggesting its potential to serve as a novel diagnostic tool. The versatility of sensing the RNA expression level can perhaps take advantage of known mapping between RNA expression profiles of pathogens and the resistance they carry [45, 46] . Aside from detecting RNA molecules, cell-free systems can also sense non-RNA molecules that are associated with certain bacterial pathogens [44] .
Cell-free systems are not self-sustainable for in vivo longterm monitoring and the sophistication of circuit functions is often limited due to the platform constraints. In comparison, sensors based on living cells can offer greater versatility in circuit functions and in their operation. For instance, a recent study demonstrated the use of engineered Escherichia coli carrying a genetic toggle switch to record an environmental signal in living animals [47] (Fig. 2B) . A model chemical (anhydrotetracycline) is used in this study but the design can be adapted to sense biomarkers of interest, including those associated with bacterial infections [48] . Along the same line, another study demonstrated the engineering of a probiotic strain of E. coli (Nissle 1917) to sense thiosulfate and tetrathionate, which are associated with a gut inflammation mouse model infected by Salmonella typhimurium [49, 50] . Such whole-cell sensors have the potential of being used for continuous monitoring of host environments for biomarkers associated with bacterial infections.
In the long-term, such engineered cell-based sensors can benefit from a number of recent developments in synthetic biology. For instance, the examples listed above focus on sensing small molecules. The sensing capability can be further expanded by incorporating additional sensing and actuating functions, such as those based on engineered protein switches [51, 52] . Moreover, instead of storing the sensory information by regulating gene expression, the memory recorded in DNA molecules in single cells through stimuliresponsive genome editing can provide relatively more stable memory storage [53, 54] . In addition, engineered microbial communities can also be used to implement memory capabilities [55] .
As viruses that infect bacteria, phages typically have a narrow host range, which can also be exploited for the detection of specific living pathogens [56] (Fig. 2C) . To facilitate detection and quantification, engineered phages have been equipped with a wide range of reporter genes, which code for fluorescence [57] or enzymatic activities [58e60]. These readouts are often more rapid to quantify and require less steps than plaque assays or immunoassays [61] . In addition to detection, engineered phages can be used to quantify bacterial response to antibiotic treatments with high sensitivity [62e64]. Although most phages have narrow host ranges, which enable detection with high specificity, this property often necessitates the identification and optimization of phages to target one or a group of specific bacterial hosts of interest. However, detection and quantification of multiple different host bacteria can be achieved by using well-defined phage cocktails [65] .
Diagnostics based on phenotypic profiling
Sequence-based techniques may not provide sufficient information on drug responses due to the complexity of genotype-phenotype mapping [17, 66] . Direct measurements of drug responses may then be preferable. However, current drug susceptibility assays (e.g. disk diffusion assays) have long turnaround time (typically 16e24 h after isolation) [67] and usually indicate only minimum inhibitory concentration [21] , which is the lowest concentration required to completely inhibit bacterial growth.
Technologies that enable faster and more accurate quantifications of antimicrobial susceptibility are required. These technologies are based on phenotypic 
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Synthetic biology based diagnostic tools. A. A toehold switch can detect a RNA molecule with a pre-defined sequence. This sequence can be designed to detect the expression of resistant genes or other genes that can identify a certain pathogen. When the target RNA molecule is not present, a hairpin structure forms and represses the expression of reporter proteins. Once the target RNA molecule is present and bound, the hairpin opens and the expression of the reporter is activated. B. A whole cell sensor that records environmental signal (red) through a trigger module that activates the memory module to generate a sustained output signal (purple). C. Phages provide a sensitive detection method for the presence of a certain bacterial host through rapid propagation of phages and expression of an easy-to-detect readout. Besides improving technologies for better phenotypic profiling, it is equally, if not more important to utilize quantitative biology to reveal the rich information content imbedded in these measurements. Because of the complex interplay between bacterial populations and their environment, the growth dynamics of a population can serve as unique phenotypic signatures of the population. To demonstrate feasibility, a recent study used growth curves in a liquid culture with high temporal resolution to identify bacteria at a strain level (including pathogenic strains) [72] . Bacterial growth in the spatial dimension, such as bacterial colony growth can also provide information for diagnosis. High-resolution quantification of bacterial growth on agar plates (quantified by image scanners) has been used to deduce phenotypic parameters associated with antibiotic susceptibility, antibiotic tolerance and potential to develop resistance [73, 74] . Due to the abundant information, temporal and spatial growth dynamics of bacteria can potentially serve as the basis for strain-level identification of pathogens, antibiotic susceptibility test, and evaluation of the likelihood of resistance acquisition.
Treatments
Considering that much of the antibiotic resistance crisis is likely due to overuse or misuse of antibiotics, more effective use of antibiotics is critical for alleviating the crisis. At the global level, this goal has been partially addressed through restricting non-medical use of antibiotics [75] and, in the clinical setting, through antibiotic stewardship programs [76] . For individual patients, proper use of antibiotics requires the optimal design of dosing protocols and drug combinations. Both needs can benefit from a better quantitative understanding of bacterial antibiotic response. In addition, alternative treatment strategies, including those based on synthetic biological systems, can complement the use of antibiotics.
Effective use of existing antibiotics
Improvement in antibiotic usage, especially multi-dose regimens and multi-drug combinations, has shown promise in increasing treatment efficacy [77] , delaying emergence of antibiotic resistance [78] , and reversing resistance [12] . Such design is often built on a quantitative understanding and characterizations of bacterial responses to certain antibiotics. Using computational modeling, a recent study demonstrates how the temporal response of a bacterial population to a single dose of antibiotic treatment can be used to optimize multidosing protocols [79] . The strategy can also be generalized to mixed populations consisting of persister cells and sensitive populations [79] .
While combination therapy represents a promising strategy to bacterial pathogens [80] , determining optimal combinations can be a daunting task: the number of possible pairs and triplets increase combinatorially with the number of available drugs. To address this challenge, a recent study used quantitative biology tools coupled with appropriate experimental design to demonstrate that the response to drug pairs at several doses can predict responses to three or more drugs at all doses [81] . This allows the design of an optimal multi-drug combination with manageable experiments. Prediction of potent drug combinations can also benefit from integrating other sources of information, such as chemogenomics data which indicate the drug targets of antibiotics [82] .
When designing an antibiotic treatment, evolutionary dynamics should also be exploited to reduce selection for or even select against resistant bacteria. Evidence is mounting that mutational pathways toward resistance are constrained depending on the antibiotics used [83, 84] . Exploiting these limited mutational pathways can allow design of dosing protocols that eliminate infection while minimizing resistance evolution. It is then important to predict how quickly resistance will develop and whether the mutational pathway is consistent for a given drug. For this, variability in resistance strength and perturbation of growth rates across different antibiotic treatments may serve as predictive quantitative parameters [85] . In the case of multi-drug treatments, negative cross resistance (i.e. the phenomenon that increasing resistance to one antibiotic leads to collateral sensitivity of another) is predictive of whether cycling two antibiotics will slow down evolution [86] . These strategies may extend beyond de novo mutation, with selection potentially governing horizontal gene transfer dynamics as well [87] . Ultimately, treatment strategy may become a balance between applying strong selective pressure (i.e. rapid clearance of infection) and minimizing chance of resistance (i.e. drawn out evolutionary manipulation) [12] .
Alternative treatments using synthetic biology
Beyond better use of existing antibiotics, alternative treatment strategies involving synthetic biology may decrease our dependence on antibiotics and reduce overall selection pressure on resistant bacteria in the long term.
In addition to serving as a novel diagnostic tool, the ability of phages to infect and potentially lyse specific hosts have also been evaluated for their utility as therapeutics. Phage therapies are attractive especially for its ability to treat infections caused by multidrug resistant bacterial pathogens [88] . In contrast to antibiotics, phage therapeutics have several distinct properties. One property is the ability of phages to increase in number during treatments, which allows low doses and the potential to use a single dose for successful treatments [89] . Along the same line, phages can also coevolve with their bacterial hosts during treatment, keeping even the most abundant bacteria in check [88, 90] . Although bacterial pathogens can also develop resistance to phages, ineffectual phages can be improved via mutagenesis [91] and phage-resistant bacteria may also exhibit reduced virulence [92] . Another property of natural phages is their narrow host ranges which allow the protection of commensal microflora, resulting in fewer side effects than therapies based on broadspectrum antibiotics [89] . However, when the narrow host range limits the therapeutic generalizability of phages, it may be overcome through the development of carefully-designed phage cocktails [93] or by engineering phages with broadened host range through, for example, modulation of tail fiber compositions [94, 95] .
To enhance their efficacy, phages have been engineered to encode effectors to target different aspects of the host bacteria. Biofilms are complex structures formed by bacterial cells and a matrix of extracellular polymeric substances, which serve as a physical barrier that can reduce penetration of antibiotics [96] . Furthermore, bacterial cells in biofilms exhibit a high degree of genetic and phenotypic heterogeneity and often contain subpopulations (e.g. persisters) that are highly tolerant against antibiotics. As such, the function to target biofilms makes engineered phages more effective in targeting bacterial pathogens or serve as an adjuvant to antibiotic treatment. For instance, an engineered T7 phage encoding a biofilm-dispersal enzyme exhibited greater efficiency than the wild-type T7 phage in targeting biofilm-forming bacteria [97] .
In addition, phages have also been engineered to target antibiotic resistant pathogens by silencing the responsible genes (Fig. 3A) [98, 99] or by using these genes as a cue to increase specificity [100e102]. These developments have benefited from the recent advancements in genome-editing tools, such as clustered 
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Synthetic biology based treatment tools. A. Engineered M13 phage deliver antisense antimicrobial RNA (blue) to silence the mRNA of resistance gene (red) through enhancing degradation and inhibit translation through base pairing. B. Engineered bacteriophages deliver CRISPR-Cas systems that kill the host cell by cleaving the host chromosomal DNA in response to the sensing of target genes (e.g., those encoding resistance and virulence). C. Engineered probiotics can recognize specific molecules which then trigger the secretion of antibiofilm and antimicrobials that disrupt bacterial pathogens with different mode of activities.
regularly interspaced short palindromic repeats-CRISPR associated genes (CRISPR-Cas). Specifically, RNA-guided Cas9 has been used in engineered phages to sense the presence of specific antibiotic resistance genes and to kill the corresponding host cells by cleaving their chromosomal DNA (Fig. 3B) [100e102] . Due to the specificity of the treatment, the method can preserve commensal bacteria, which if disturbed can lead to adverse effect such as Clostridium difficile infection [20] . Alternatively, CRISPR-Cas system carried by a temperate phage has been used to remove antibiotic resistance genes while giving protection against lysis. By providing a fitness benefit in exchange for resistance, such treatments have the potential to enhance the longevity of antibiotics against evolving targets [99] .
Due to their small genome size, engineered phages have limited number of exogenous genes that can be introduced. Engineered whole-cell systems therefore offer higher flexibility and programmability. Engineered probiotics and commensal bacterial cells can have a diverse range of capabilities, including delivery of antimicrobial, delivery of antibiotic adjuvants, virulence inhibition, toxin neutralization and adhesion prevention [103] . When coupled with sensory capabilities, engineered bacteria could provide streamlined treatment and prevention of bacterial infections. This capability has been demonstrated in several cases. Lactococcus lactis was engineered to detect Enterococcus faecalis by sensing enterococcal pheromone and subsequently expressing an antimicrobial peptide to inhibit E. faecium [104] . E. coli was engineered to sense small molecules secreted by Pseudomonas aeruginosa to induce expression of a bacteriocin that targets P. aeruginosa [105] . E. coli was programmed to localize to P. aeruginosa and deploy an antimicrobial peptide and biofilm dispersing enzyme to kill P. aeruginosa [106] (Fig. 3C) . A recent study demonstrated in vivo efficacy of an engineered E. coli strain to sense, treat and prevent P. aeruginosa gut infection in animal models [107] . Moving beyond traditional model organisms, a recent study demonstrated the capability to engineer a non-model organism Bacteroides thetaiotaomicron, an abundant and stable component of the human gut microbiome. The engineered B. thetaiotaomicron can colonize in the mouse gut to sense and respond to stimuli [108] .
Although engineered bacteria have great potential to become living therapeutics, introduction of engineered bacteria into human host can pose safety concerns as engineered bacteria may evolve and spread to the environment, causing unintended negative impacts to the human host and beyond. To combat this, engineered safeguard mechanisms have been developed to prevent unintended proliferation of engineered bacteria by killing bacteria that escape from spatial confinement [109] or by controlling the death or survival of engineered bacteria through specific chemical cues [110] . Antibiotic can diffuse into cells and be degraded intracellularly. Antibiotic-mediated cell lysis can trigger the release of b-lactamase to the environment to degrade antibiotics extracellularly. C. Cooperator produces public good, which imposes a cost to itself. Cheaters exploit public good without producing it. In a mixture of cooperators and cheaters, depending on the conditions, antibiotic selection can lead to selection of either cooperators or cheaters. D. Quorum sensing (QS) is a mechanism by which a signal molecule is produced and sensed by a population to regulate the expression effector proteins. When the population density is high, QS signaling molecules accumulate to a high concentration and trigger the expression of proteins involved in virulence, biofilm formation and antibiotic resistance. When population density is low, the expression of these proteins is not triggered (denoted by ∅).
Quantitative , where a population survives antibiotic treatment only when initial population density is sufficiently high (Fig. 4A) . This density-dependent survival can emerge from different mechanisms [13] . A common example of collective antibiotic tolerance is the response to b-lactam antibiotics where cells express b-lactamases to collectively degrade the antibiotic (Fig. 4B ). As such, treating b-lactam producing strains by blocking the activity of b-lactamases through adjuvant inhibitors like tazobactam and sulbactam has emerged as an effective strategy. However, one study found through computational modeling and experimental results that insufficient blocking can also lead to unintended spread of antibiotic resistance due to the interaction between a b-lactamase producing strain and a cheater strain [113] . This study highlights the importance of population dynamics in treatment design.
Antibiotic treatments can also alter the interplay between cooperators and cheaters which can impact treatment outcomes (Fig. 4C) . P. aeruginosa can cooperate through production of siderophores that chelate iron in the environment as a public good. In a mixture of siderophore-producing cooperators and non-producing cheaters, sub-inhibitory concentrations of gentamicin can increase the fitness advantage of the cheaters, causing a decline in the cooperator strain [114] . Interestingly, this study found that the evolved resistance reaches the highest frequency in a mixture of the producer strain and the non-producer strain compared with monocultures. Using a mathematical model, the authors provided explanations to the experimental observations and established a general principle underlying the interplay between stress resistance and cheaterecooperator interaction [114] . In a different example, S. typhimurium is a pathogen that exhibits cooperative virulence. Expression of virulence factors is costly for individual S. typhimurium, but is beneficial at the population level. In contrast to the antibiotic treatment response in P. aeruginosa, antibiotic treatment of S. typhimurium has the potential to increase the virulent cooperator strain and increase disease transmission, which is possibly due to differential selection created by spatial structure [115] . These opposite responses to antibiotic treatment demonstrate the importance of understanding cooperator-cheater dynamics during the response to specific antibiotics.
Quorum sensing (QS) is a mechanism by which bacteria produce and sense small molecule signals to regulate gene expressions based on population size. Given the diverse roles of QS in regulating antibiotic resistance, virulence and biofilm formation, it has been suggested as a potential target for inhibiting bacterial survival or virulence [116, 117] (Fig. 4D) 
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